Lagunita BioSciences

Lagunita BioSciences is a venture capital firm and incubator based in Menlo Park, California, established in 2015. The company focuses on creating and nurturing early-stage enterprises that aim to commercialize innovative translational science to meet critical clinical needs. Its investment strategy encompasses sectors such as ophthalmology, drug discovery, oncology, medical devices, and digital health, positioning Lagunita BioSciences as a pivotal player in advancing healthcare solutions.

Christine Banian

Director

Thomas Krummel

Venture Partner

David Myung

Venture Partner

Daniel Palanker Ph.D

Venture Partner

6 past transactions

Kedalion Therapeutics

Series B in 2021
Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, that specializes in developing innovative therapies for eye care. Founded in 2015, the company has created a technology that delivers topical ophthalmic drugs with a high degree of precision and accuracy. This method allows for comparable efficacy while reducing the required dosage by 80% compared to standard eye drops. Kedalion's approach not only enhances patient comfort and convenience during self-administration but also improves the side effect profile of the medications. By focusing on reducing the burden on healthcare systems and enhancing the experience for both healthcare professionals and patients, Kedalion Therapeutics aims to transform the landscape of ophthalmic treatments.

Kedalion Therapeutics

Series A in 2018
Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, that specializes in developing innovative therapies for eye care. Founded in 2015, the company has created a technology that delivers topical ophthalmic drugs with a high degree of precision and accuracy. This method allows for comparable efficacy while reducing the required dosage by 80% compared to standard eye drops. Kedalion's approach not only enhances patient comfort and convenience during self-administration but also improves the side effect profile of the medications. By focusing on reducing the burden on healthcare systems and enhancing the experience for both healthcare professionals and patients, Kedalion Therapeutics aims to transform the landscape of ophthalmic treatments.

Verana Health

Series C in 2018
Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.

ViewPoint Therapeutics

Series B in 2018
ViewPoint Therapeutics, a biotechnology company founded in 2014 and based in San Francisco, focuses on developing treatments for diseases caused by protein misfolding, particularly cataracts. The company is advancing its research on crystallin stabilizers, which are small molecules designed to prevent and treat age-related cataracts and presbyopia. These stabilizers have shown promise in preclinical models through a systematic screening and optimization process. By targeting protein misfolding, ViewPoint Therapeutics aims to provide effective therapies for common age-related disorders, including cataracts and neurodegenerative diseases, ultimately enhancing treatment options for physicians and their patients.

ViewPoint Therapeutics

Series A in 2016
ViewPoint Therapeutics, a biotechnology company founded in 2014 and based in San Francisco, focuses on developing treatments for diseases caused by protein misfolding, particularly cataracts. The company is advancing its research on crystallin stabilizers, which are small molecules designed to prevent and treat age-related cataracts and presbyopia. These stabilizers have shown promise in preclinical models through a systematic screening and optimization process. By targeting protein misfolding, ViewPoint Therapeutics aims to provide effective therapies for common age-related disorders, including cataracts and neurodegenerative diseases, ultimately enhancing treatment options for physicians and their patients.

Verana Health

Series B in 2015
Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.